Amcad Biomed (ROCO:4188) Tax Provision : NT$0.00 Mil (TTM As of Mar. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Amcad Biomed Tax Provision?

Amcad Biomed's tax provision for the three months ended in Mar. 2024 was NT$0.00 Mil. Its tax provision for the trailing twelve months (TTM) ended in Mar. 2024 was NT$0.00 Mil.

Amcad Biomed Tax Provision Historical Data

The historical data trend for Amcad Biomed's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amcad Biomed Tax Provision Chart

Amcad Biomed Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Tax Provision

Get a 7-Day Free Trial

Amcad Biomed Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Tax Provision	Get a 7-Day Free Trial															-	-	-	-	-

Amcad Biomed Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$0.00 Mil.

Amcad Biomed (ROCO:4188) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Amcad Biomed Corp (ROCO:4188) » Definitions » Tax Provision

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 167, Fuxing North Road, 5th Floor, Zhongshan District, Taipei, TWN, 104

Website

https://www.amcad.com.tw

Amcad Biomed Corp develops computer-aided detection and diagnosis(CADe/CADx) software devices. Its product pipeline includes AmCAD-UT Detection, a software solution for thyroid nodules analysis; AmCAD-UV, a software device that is used for quantifying and classifying the ultrasonic color intensity data acquired from FDA-cleared ultrasound systems and displaying the noise-reduced color-coded pulsatile signals; AmCAD- U.S, a software device for viewing and quantifying ultrasound image data of backscattered signals; and AmCAD-UO offers detection for obstructive sleep apnea on awake patients to identify the root cause of sleep apnea. The company's geographical segments include Taiwan, China, and other countries, out of which the majority of the revenue is generated from China.

Amcad Biomed (ROCO:4188) Headlines

No Headlines